Skip to main content
Premium Trial:

Request an Annual Quote

Isis to Receive $1.4M from Alnylam Following Monsanto Deal


Isis Pharmaceuticals this week said it will receive a $1.4 million payment from Alnylam following that company's establishment of a technology- and intellectual property-licensing deal with agbio firm Monsanto.

Last week, Alnylam announced that it has struck a deal giving Monsanto exclusive, worldwide rights to its RNAi technology and IP for agricultural applications (GSN 9/6/2012).

In 2004, Alnylam and Isis forged an IP arrangement, with each gaining access to the others' IP for use in their respective fields (GSN 3/19/2004). Pursuant to the terms of that arrangement, Isis stands to receive $1.4 million of the $29.2 million that Alnylam received upfront from Monsanto, as well as an undisclosed portion of future milestones and royalties.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.